{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T22:54:47Z","timestamp":1770418487188,"version":"3.49.0"},"reference-count":47,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T00:00:00Z","timestamp":1565913600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Despite the significant progress in Rheumatoid Arthritis (RA) therapeutics, there are several reports in the literature claiming that the size of unmet needs in RA is large. In the era before biologics, there was indeed a significant number of patients who did not achieve low disease activity (LDA) or disease remission due to limited therapeutic choices in the doctors\u2019 armamentarium. Treatment wise, great progress has been achieved over the last decades with the discovery and introduction in therapeutics of new molecules, such as the biological (b) disease-modifying anti-rheumatic drugs (DMARDs), and the targeted synthetic (ts) DMARDs. Today, with such a plethora of conventional synthetic (cs) DMARDs, tsDMARDs, and bDMARDs, why are we unable to successfully treat RA patients? What is wrong? However, a new drug for RA does not mean it is necessary to switch to a new treatment. It is very easy to change and switch therapies when the patient complains about pain and stiffness. In this setting, it is obligatory to rule out other comorbidities and disorders that may be the cause of the pain first. Thus, clinicians must have a deep knowledge of the drug therapy and be able to adjust the treatment when needed. A minute clinical examination must be carried out on every visit with close monitoring of the patient. A treat-to-target (T2T) approach and the application of the American College of Rheumatology\/European League Against Rheumatism (ACR\/EULAR) recommendations and strategies should minimize the unmet needs.<\/jats:p>","DOI":"10.3390\/jcm8081237","type":"journal-article","created":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T06:10:14Z","timestamp":1566195014000},"page":"1237","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["Rheumatoid Arthritis Treatment. A Back to the Drawing Board Project or High Expectations for Low Unmet Needs?"],"prefix":"10.3390","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2232-0326","authenticated-orcid":false,"given":"Alexandros A.","family":"Drosos","sequence":"first","affiliation":[{"name":"Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9383-5722","authenticated-orcid":false,"given":"Eleftherios","family":"Pelechas","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5193-2284","authenticated-orcid":false,"given":"Paraskevi V.","family":"Voulgari","sequence":"additional","affiliation":[{"name":"Rheumatology Clinic, Department of Internal Medicine, Medical School, University of Ioannina, 45110 Ioannina, Greece"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Pelechas, E. (2019). Rheumatoid Arthritis. Illustrated Handbook of Rheumatic and Musculo-Skeletal Diseases, Springer.","DOI":"10.1007\/978-3-030-03664-5"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.autrev.2004.09.002","article-title":"Epidemiology of adult rheumatoid arthritis","volume":"4","author":"Alamanos","year":"2005","journal-title":"Autoimmun. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.semarthrit.2006.08.006","article-title":"Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: A systematic review","volume":"36","author":"Alamanos","year":"2006","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.jbspin.2012.02.005","article-title":"Mortality in rheumatoid arthritis over the last fifty years: Systematic review and meta-analysis","volume":"80","author":"Dadoun","year":"2013","journal-title":"Joint Bone Spine"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheumatol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria. An American College of Rheumatology\/European League against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Pelechas, E., Voulgari, P.V., and Drosos, A.A. (2019). Golimumab for Rheumatoid Arthritis. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030387"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Aaltonen, K.J., Virkki, L.M., Malmivaara, A., Konttinen, Y.T., Nordstrom, D.C., and Blom, M. (2012). Systematic review and meta-analysis of the efficacy and safety of existing TNF blocking agents in treatment of rheumatoid arthritis. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0030275"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1007\/s40265-017-0829-7","article-title":"Tocilizumab: A Review in Rheumatoid Arthritis","volume":"77","author":"Scott","year":"2017","journal-title":"Drugs"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1517\/14712598.2011.592825","article-title":"Abatacept: A biologic immune modulator for rheumatoid arthritis","volume":"11","author":"Papagoras","year":"2011","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.2147\/DDDT.S139248","article-title":"Current perspective on rituximab in rheumatic diseases","volume":"11","author":"Schioppo","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1146\/annurev-med-051113-024537","article-title":"The JAK-STAT pathway: Impact on human disease and therapeutic intervention","volume":"66","author":"Schwartz","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1136\/annrheumdis-2016-210094","article-title":"Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: Results from the RA-BUILD study","volume":"76","author":"Doiugados","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann. Rheum. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1136\/annrheumdis-2016-210715","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update","volume":"76","author":"Smolen","year":"2017","journal-title":"Ann. Rheum. Dis."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1002\/acr.21649","article-title":"Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice","volume":"64","author":"Anderson","year":"2012","journal-title":"Arthritis Care Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/art.1780380107","article-title":"Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis","volume":"38","author":"Prevoo","year":"1995","journal-title":"Arthritis Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.semarthrit.2013.07.011","article-title":"Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival","volume":"43","author":"Flouri","year":"2014","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"65","DOI":"10.4236\/ojra.2013.32011","article-title":"Unmet needs in the treatment of rheumatoid arthritis","volume":"3","author":"Pope","year":"2013","journal-title":"Open J. Rheumatol. Autoimmune Dis."},{"key":"ref_21","first-page":"1135","article-title":"Difficult-to-treat rheumatoid arthritis: An area of unmet clinical need","volume":"57","author":"Jacobs","year":"2017","journal-title":"Rheumatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1016\/j.autrev.2017.07.012","article-title":"International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritides, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren\u2019s syndrome)? The unmet needs and the clinical grey zone in autoimmune disease management","volume":"16","author":"Giacomelli","year":"2017","journal-title":"Autoimmun. Rev."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1007\/s00296-015-3415-x","article-title":"A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: A current perspective","volume":"36","author":"Taylor","year":"2016","journal-title":"Rheumatol. Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1093\/rheumatology\/key338","article-title":"Assessments of the unmet need in the management of patients with rheumatoid arthritis: Analyses from the NOR-DMARD registry","volume":"58","author":"Olsen","year":"2019","journal-title":"Rheumatology"},{"key":"ref_25","first-page":"69","article-title":"The unmet need in rheumatology: Reports from the Targeted Therapies meeting 2016","volume":"34","author":"Winthrop","year":"2016","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/BF02114393","article-title":"Methotrexate therapy in rheumatoid arthritis. A two year prospective follow-up","volume":"9","author":"Drosos","year":"1990","journal-title":"Clin. Rheumatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1007\/BF02114394","article-title":"Can treatment with methotrexate influence the radiological progression of rheumatoid arthritis?","volume":"9","author":"Drosos","year":"1990","journal-title":"Clin. Rheumatol."},{"key":"ref_28","first-page":"580","article-title":"D-penicillamine in early rheumatoid arthritis","volume":"15","author":"Drosos","year":"1997","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_29","first-page":"695","article-title":"Cyclosporine A in the treatment of early rheumatoid arthritis. A prospective, randomized 24-month study","volume":"16","author":"Drosos","year":"1998","journal-title":"Clin. Exp. Rheumatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1056\/NEJMhle1800125","article-title":"Rationale, Opportunities, and Reality of Biosimilar Medications","volume":"378","author":"Lyman","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/14712598.2018.1430760","article-title":"ABP 501 for the treatment of rheumatoid arthritis","volume":"18","author":"Pelechas","year":"2018","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1080\/14712598.2019.1566456","article-title":"Etanercept biosimilar SB-4","volume":"19","author":"Pelechas","year":"2019","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Mueller, R.B., Spaeth, M., von Restorff, C., Ackermann, C., Schulze-Koops, H., and von Kempis, J. (2019). Superiority of a Treat-to-Target Strategy over Conventional Treatment with Fixed csDMARD and Corticosteroids: A Multi-Center Randomized Controlled Trial in RA Patients with an Inadequate Response to Conventional Synthetic DMARDs, and New Therapy with Certolizumab Pegol. J. Clin. Med., 8.","DOI":"10.3390\/jcm8030302"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Taylor, P.C., Balsa Criado, A., Mongey, A.B., Avouac, J., Marotte, H., and Mueller, R.B. (2019). How to Get the Most from Methotrexate (MTX) Treatment for Your Rheumatoid Arthritis Patient?-MTX in the Treat-to-Target Strategy. J. Clin. Med., 8.","DOI":"10.3390\/jcm8040515"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e000371","DOI":"10.1136\/rmdopen-2016-000371","article-title":"Systematic review and network meta-analysis of the efficacy and safety of tumour necrosis factor inhibitor-methotrexate combination therapy versus triple therapy in rheumatoid arthritis","volume":"3","author":"Fleischmann","year":"2017","journal-title":"RMD Open"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1002\/acr.23255","article-title":"Rheumatoid Arthritis Treatment After Methotrexate: The Durability of Triple Therapy Versus Etanercept","volume":"69","author":"Peper","year":"2017","journal-title":"Arthritis Care Res."},{"key":"ref_37","first-page":"378","article-title":"Rheumatoid arthritis triple therapy compared with etanercept: Difference in infectious and gastrointestinal adverse events","volume":"56","author":"Quach","year":"2017","journal-title":"Rheumatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.semarthrit.2018.06.003","article-title":"Unmet needs in the treatment of rheumatoid arthritis. An observational study and a real-life experience from a single university center","volume":"48","author":"Kaltsonoudis","year":"2019","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(97)01300-7","article-title":"Randomised comparison of combined step-down prednisolone, methotrexate and suphasalazine with Sulphasalazine alone in early rheumatoid arthritis","volume":"350","author":"Boers","year":"1997","journal-title":"Lancet"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1002\/art.10083","article-title":"COBRA combination therapy in patients with early rheumatoid arthritis: Long-term structural benefits of a brief intervention","volume":"46","author":"Landewe","year":"2002","journal-title":"Arthritis Rheumatol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1136\/ard.2009.108027","article-title":"Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis","volume":"69","author":"Boers","year":"2010","journal-title":"Ann. Rheum. Dis."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/annrheumdis-2018-214618","article-title":"Normal mortality of the COBRA early rheumatoid arthritis trial cohort after 23 years of follow-up","volume":"78","author":"Poppelaars","year":"2019","journal-title":"Ann. Rheum. Dis."},{"key":"ref_43","first-page":"1712","article-title":"Conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial","volume":"379","author":"Geborek","year":"2010","journal-title":"Lancet"},{"key":"ref_44","first-page":"307","article-title":"Therapies for active rheumatoid arthritis after methotrexate failure","volume":"369","author":"Mikuls","year":"2014","journal-title":"N. Eng. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1002\/art.34498","article-title":"A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: The treatment of Early\/Aggressive Rheumatoid Arthritis Trial","volume":"64","author":"Moreland","year":"2012","journal-title":"Arthritis Rheumatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1056\/NEJMe1306381","article-title":"Making rational treatment decisions in rheumatoid arthritis when methotrexate fails","volume":"369","author":"Bathon","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_47","unstructured":"(2019, March 31). European Medicines Agency. Available online: https:\/\/www.ema.europa.eu\/en\/search\/search."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/8\/1237\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:11:41Z","timestamp":1760188301000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/8\/8\/1237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,16]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,8]]}},"alternative-id":["jcm8081237"],"URL":"https:\/\/doi.org\/10.3390\/jcm8081237","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,16]]}}}